FilingSEC EDGAR8-K
TScan Therapeutics Implements Retention Program for Key Personnel
· SEC accepted
StageApproved
Filing content
TScan Therapeutics approved a retention program for key employees, including the CEO and Chief Legal and Strategy Officer, involving cash awards and restricted stock units.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…